Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of inducement awards to new employees. The company issued 105,330 restricted stock units (RSUs) to seven newly hired employees.
The RSUs will vest over a four-year period, with equal installments vesting annually on the grant date anniversary. The awards were granted under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Solid Biosciences (Nasdaq: SLDB), un'azienda nel settore delle scienze della vita specializzata nello sviluppo di terapie genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato l'assegnazione di premi di incentivo a nuovi dipendenti. La societ脿 ha emesso 105.330 unit脿 azionarie vincolate (RSU) a sette nuovi assunti.
Le RSU matureranno in un periodo di quattro anni, con rate uguali che maturano ogni anno alla ricorrenza della data di assegnazione. I premi sono stati concessi nell'ambito del Piano di Incentivi Azionari 2024 della Societ脿 e rispettano la Regola di Quotazione Nasdaq 5635(c)(4), fungendo da incentivo per l'accettazione dell'impiego.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida enfocada en desarrollar medicinas gen茅ticas de precisi贸n para enfermedades neuromusculares y card铆acas, ha anunciado la concesi贸n de premios de incentivo a nuevos empleados. La compa帽铆a emiti贸 105,330 unidades restringidas de acciones (RSU) a siete empleados reci茅n contratados.
Las RSU se consolidar谩n durante un per铆odo de cuatro a帽os, con cuotas iguales que se consolidan anualmente en el aniversario de la fecha de concesi贸n. Los premios fueron otorgados bajo el Plan de Incentivos de Acciones de Inducci贸n 2024 de la Compa帽铆a y cumplen con la Regla de Cotizaci贸n Nasdaq 5635(c)(4), sirviendo como incentivo para la aceptaci贸n del empleo.
Solid Biosciences (雮橃姢雼�: SLDB)電� 鞁犼步攴� 氚� 鞁灔 歆堩櫂鞚� 鞙勴暅 鞝曤皜 鞙犾爠 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 靸濍獏瓿柬暀 須岇偓搿�, 鞁犾瀰 歆侅洂霌れ棎瓴� 鞙犾澑 氤挫儊鞚� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 7氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 105,330臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 氚滍枆頄堨姷雼堧嫟.
鞚� RSU電� 4雲� 霃欖晥 毵る厔 霃欖澕頃� 牍勳湪搿� 攵�鞐澕 旮半厫鞚检棎 靹膘法霅╇媹雼�. 鞚� 氤挫儊鞚� 須岇偓鞚� 2024雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅晿鞐� 瓿犾毄 靾橂澖鞚� 鞙犽弰頃橂姅 鞐暊鞚� 頃╇媹雼�.
Solid Biosciences (Nasdaq : SLDB), une entreprise des sciences de la vie sp茅cialis茅e dans le d茅veloppement de m茅dicaments g茅n茅tiques de pr茅cision pour les maladies neuromusculaires et cardiaques, a annonc茅 l'attribution de primes d'incitation 脿 de nouveaux employ茅s. La soci茅t茅 a 茅mis 105 330 unit茅s d'actions restreintes (RSU) 脿 sept nouveaux employ茅s recrut茅s.
Les RSU seront acquises sur une p茅riode de quatre ans, avec des versements 茅gaux chaque ann茅e 脿 la date anniversaire de l'octroi. Les primes ont 茅t茅 accord茅es dans le cadre du Plan d'Incitation par Actions 2024 de la soci茅t茅 et sont conformes 脿 la r猫gle de cotation Nasdaq 5635(c)(4), servant d'incitation 脿 l'acceptation de l'emploi.
Solid Biosciences (Nasdaq: SLDB), ein Life-Sciences-Unternehmen, das sich auf die Entwicklung pr盲ziser genetischer Medikamente f眉r neuromuskul盲re und Herzkrankheiten spezialisiert hat, hat die Gew盲hrung von Anreizpr盲mien an neue Mitarbeiter bekannt gegeben. Das Unternehmen hat 105.330 beschr盲nkte Aktieneinheiten (RSUs) an sieben neu eingestellte Mitarbeiter ausgegeben.
Die RSUs werden 眉ber einen Zeitraum von vier Jahren mit gleichen j盲hrlichen Raten am Jahrestag der Gew盲hrungsdatum freigegeben. Die Pr盲mien wurden im Rahmen des Inducement Stock Incentive Plans 2024 des Unternehmens gew盲hrt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4), um einen Anreiz zur Annahme der Besch盲ftigung zu bieten.
- None.
- None.
CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.聽(Nasdaq: SLDB) (the 鈥淐ompany鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units (鈥淩SUs鈥�) to seven newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee鈥檚 continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company鈥檚 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee鈥檚 acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About聽Solid Biosciences
Solid Biosciences聽is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich鈥檚 ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid鈥檚 mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit聽.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
How many RSUs did Solid Biosciences (SLDB) grant to new employees in July 2025?
What is the vesting schedule for Solid Biosciences' (SLDB) July 2025 RSU grants?
Under which plan were the Solid Biosciences (SLDB) RSU grants issued?
What happens to the Solid Biosciences (SLDB) RSU grants if employees leave the company?
